JCN Newswire
TOKYO and CAMBRIDGE, Mass., Nov 28, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD dementia (early AD).LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*…
Read More
“LEQEMBI” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea
Qiana Schroeder
23:23
TOKYO and CAMBRIDGE, Mass., Nov 28, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients
